Evidence map›Paper›PMID 37038807›Full record

ArticleJournal of Alzheimer's disease : JAD2023

Contrast Enhanced Magnetic Resonance Imaging of Amyloid-β Plaques in a Murine Alzheimer's Disease Model.

Einar Sulheim, Marius WiderØe, Marcus Bäck, K Peter R Nilsson, Per Hammarström, Lars N G Nilsson, Catharina de Lange Davies, Andreas K O Åslund

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Einar SulheimDepartment of Physics, Norwegian University of Science and Technology, Trondheim, Norway.
Marius WiderØeDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.
Marcus BäckDepartment of Physics, Chemistry and Biology, Division of Chemistry, Linköping University, Linköping, Sweden.
K Peter R NilssonDepartment of Physics, Chemistry and Biology, Division of Chemistry, Linköping University, Linköping, Sweden.
Per HammarströmDepartment of Physics, Chemistry and Biology, Division of Chemistry, Linköping University, Linköping, Sweden.
Lars N G NilssonDepartment of Pharmacology, University of Oslo and Oslo University Hospital, Oslo, Norway.
Catharina de Lange DaviesDepartment of Physics, Norwegian University of Science and Technology, Trondheim, Norway.
Andreas K O ÅslundDepartment of Physics, Norwegian University of Science and Technology, Trondheim, Norway.
Linköping University · SENorwegian University of Science and Technology · NOSINTEF · NOOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEarly detection of amyloid-β (Aβ) aggregates is a critical step to improve the treatment of Alzheimer's disease (AD) because neuronal damage by the Aβ aggregates occurs before clinical symptoms are apparent. We have previously shown that luminescent conjugated oligothiophenes (LCOs), which are highly specific towards protein aggregates of Aβ, can be used to fluorescently label amyloid plaque in living rodents.

objectiveWe hypothesize that the LCO can be used to target gadolinium to the amyloid plaque and hence make the plaque detectable by T1-weighted magnetic resonance imaging (MRI).

methodsA novel LCO-gadolinium construct was synthesized to selectively bind to Aβ plaques and give contrast in conventional T1-weighted MR images after intravenous injection in Tg-APPSwe mice.

resultsWe found that mice with high plaque-burden could be identified using the LCO-Gd constructs by conventional MRI.

conclusionOur study shows that MR imaging of amyloid plaques is challenging but feasible, and hence contrast-mediated MR imaging could be a valuable tool for early AD detection.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsBrainDisease Models, AnimalGadoliniumMagnetic Resonance ImagingMiceMice, TransgenicPlaque, AmyloidAmyloid beta-PeptidesGadoliniumAlzheimer’s diseaseamyloid-β (Aβ)fluorescencemagnetic resonance imagingmultimodal imaging

Identifiers

PMID37038807
PMCPMC10200222
OpenAlexW4362551316

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.